Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
TRIB3 siRNA
- Development stage
- Preclinical
- Lead developer
- Chung Shan Medical University
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
01
Overview
TRIB3 siRNA is a small interfering RNA (siRNA) designed to silence the expression of tribbles pseudokinase 3 (TRIB3), a member of the tribbles family of scaffold proteins. TRIB3 lacks significant kinase activity but modulates various signaling pathways, including the AKT, MAPK, and TGF-β pathways, and is often upregulated in response to cellular stress. In oncological research, particularly in endometrial cancer, TRIB3 has been identified as a key regulator of cancer stem cell (CSC) maintenance through its interaction with the transcription factor ELF4, which subsequently promotes the expression of CDK6. By targeting TRIB3 mRNA for degradation, TRIB3 siRNA reduces TRIB3 protein levels, leading to decreased CDK6 expression and inhibition of CSC-related properties such as tumorsphere formation and the expression of stemness markers like OCT4 and NANOG.
- Other names
- siTRIB3siTRIB-3siTRIB 3tribbles pseudokinase 3 siRNA
02
Targets
TRIB3
Beyond the preview
Go deeper on TRIB3 siRNA.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on TRIB3 siRNA.